{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:51:53Z","timestamp":1789487513880,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pregnant patients with cancer are routinely excluded from the clinical trials, limiting the evidence to guide the management of advanced malignancies during pregnancy. Data regarding maternal and neonatal outcomes associated with genotype\u2010directed therapy for non\u2010small cell lung cancer (NSCLC) during pregnancy remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective multicenter, pooled analysis of pregnant patients diagnosed with NSCLC between 2002 and 2024 who were enrolled in the Cancer and Pregnancy Registry (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT02749474). Consecutive cases diagnosed during pregnancy were included. Clinical presentation, tumor histology and stage, biomarker and molecular profiling, oncologic treatment administered during pregnancy, obstetric management, maternal outcomes, and neonatal outcomes including pediatric developmental follow\u2010up were systematically reviewed and analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven pregnant patients were diagnosed with NSCLC at a median gestational age of 22.4\u2009weeks (range, 10.4\u201328.8\u2009weeks). Five patients presented with stage IV disease, one with stage III disease, and one with stage II disease. Biomarker testing identified actionable alterations in all 6 patients who underwent testing, including epidermal growth factor receptor (EGFR) mutations or amplification (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), anaplastic lymphoma kinase (ALK) rearrangement (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), and ROS1 rearrangement (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Biomarker\u2010directed therapy, including osimertinib or alectinib, was administered during the second or third trimester in 3 patients. All pregnancies resulted in live births, including one dichorionic diamniotic twin gestation, yielding eight infants. Median gestational age at delivery was 34.9\u2009weeks. Five infants were small for gestational age, and two required early intervention for prematurity\u2010related developmental delays. No congenital anomalies or placental metastases were observed. Four patients remained alive and clinically stable at least 2.3\u2009years after diagnosis, while all mothers survived to or beyond their child's first birthday.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this limited retrospective study, biomarker\u2010directed therapy during pregnancy was associated with maternal disease control and continuation of pregnancy into later gestation in selected patients. No major fetal toxicity signal was identified; however, these findings should not be interpreted as establishing the safety of targeted therapy during pregnancy. Early biomarker testing and individualized multidisciplinary management may help inform treatment decision\u2010making for carefully selected patients with NSCLC diagnosed during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/aogs.70303","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:15:03Z","timestamp":1783606503000},"page":"2089-2096","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotype\u2010directed therapy for non\u2013small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6398-9652","authenticated-orcid":false,"given":"Reed","family":"Firestone","sequence":"first","affiliation":[{"name":"Department of Medicine Thomas Jefferson University Hospital  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gaughan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics\/Research Cooper Medical School at Rowan University  Camden New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyce","family":"Cardonick","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Cooper University Hospital  Camden New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32829"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716347"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.09.002"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-234"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-999"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.09.019"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31819c8674"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2015.12.004"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.09.001"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.005"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.11.006"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1300"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.03.026"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.08.008"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2018.03.007"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.10.025"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1108124"},{"issue":"7","key":"e_1_2_13_19_1","article-title":"Anaplastic lymphoma kinase tyrosine kinase inhibitor treatment for metastatic non\u2010small cell lung cancer throughout the entire gestation period","volume":"16","author":"Kato M","year":"2024","journal-title":"Cureus"},{"issue":"8","key":"e_1_2_13_20_1","article-title":"Two uncomplicated pregnancies on alectinib in a woman with metastatic ALK\u2010rearranged NSCLC: a case report","volume":"3","author":"Weidenbaum C","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107188"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16120"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1497302"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108456"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255575"},{"issue":"25","key":"e_1_2_13_26_1","first-page":"746","article-title":"Successful pregnancy and healthy baby outcome in a patient with tyrosine kinase inhibitor\u2010refractory ALK\u2010positive NSCLC","volume":"1556","author":"Yao Z","year":"2025","journal-title":"J Thorac Oncol"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-247530"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.01.003"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.11.012"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1784859"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.06.003"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv172"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.70303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aogs.70303","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.70303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:26:56Z","timestamp":1789482416000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.70303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/aogs.70303"],"URL":"https:\/\/doi.org\/10.1111\/aogs.70303","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"2026-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}